Status:
COMPLETED
Affect Treatment for Depression and Anxiety (TAD Pilot)
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Southern Methodist University
Conditions:
Depression
Anxiety
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The goal of this study is to determine whether subjects who do not show expected clinical improvement during the early course of positive affect treatment (PAT) would benefit from switching to an alte...
Detailed Description
Anhedonia, or loss of interest or pleasure in usual activities, is characteristic of depression, some types of anxiety, as well as substance abuse and schizophrenia. Specifically, anhedonia is associa...
Eligibility Criteria
Inclusion
- English-speaking
- Low positive affect indexed by less than or equal to 24 on the positive affect subscale of the PANAS (i.e., PANAS-P); and scores of greater than or equal to 11 for depression and greater to or equal to 6 for anxiety on the Depression, Anxiety, and Stress Scale.
- Score of greater than or equal to 4 on any WSAS subscale
- Willingness to refrain from starting other psychosocial or pharmacological treatments until study completion.
Exclusion
- Patient report of serious medical conditions - such as history of serious, uncontrolled medical illness, or instability (including significant cardio-pulmonary disease, organic brain syndrome, seizure disorder, cerebrovascular disease, thyroid dysfunction, and diabetes)
- Current active suicidal ideation
- Lifetime history of bipolar disorder, psychosis, cognitive impairment, or organic brain damage
- Substance use disorder (including smoking) within the last 6 months. History of cocaine or stimulate use (e.g., amphetamine, cocaine, methamphetamine)
- Greater than 11 cigarettes per week or nicotine equivalent
- History of marijuana, cocaine or stimulant use 5-7 times/week or more before age 15 (e.g., amphetamine, cocaine, methamphetamine)
- Willingness to refrain from marijuana use 1 week before laboratory assessments
- Pregnancy
- Bupropion, dopaminergic or neuroleptic medications use in the past 6 months
- Heterocyclics and SSRIs are permitted if stabilized (3 months) and PRN benzodiazepines and beta-blockers are permitted but discouraged on laboratory assessment visits
- Refusal of video/audio-taping
- Prior participation in previous waves of this study
Key Trial Info
Start Date :
March 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06488859
Start Date
March 25 2024
End Date
March 25 2025
Last Update
May 11 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095
2
Southern Methodist University
Dallas, Texas, United States, 75205